Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue

Blood (2022) 139 (7): 1039–1051.

https://doi.org/10.1182/blood.2021011980

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG

Blood (2021) 138 (Supplement 1): 2360.

https://doi.org/10.1182/blood-2021-148041

Published: 2021

Journal Articles

Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136064

Published: 2020

Journal Articles

Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy

Thomas Prebet, MD, Thomas Cluzeau, MDPhD, Sophie Park, MD PhD, Ulrich Germing, MD, Lionel Ades, MD PhD, Uwe Platzbecker, MD, Norbert Vey, Katharina Goetze, MD, Charikleia Kelaidi, MD, Esther Natalie Oliva, Najla H. Al Ali, BDS, MSc, Pierre Fenaux, MD PhD, Steven D. Gore, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 95.

https://doi.org/10.1182/blood.V126.23.95.95

Published: 2015

Journal Articles

Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study

Blood (2015) 126 (23): 1665.

https://doi.org/10.1182/blood.V126.23.1665.1665

Published: 2015

Journal Articles

Long-Term Outcome of Lower-Risk MDS Patients after Immunosuppressive Therapy (IST) with Anti-Thymocyte Globulin (ATG)+/- Cyclosporin A (CsA)

Charikleia Kelaidi, Thorsten Braun, Gregory Lazarian, Juliette Soret, Sophie Cereja, Virginie Eclache, Daniel Lusina, Lionel Adès, MD PhD, Antoine Martin, Pierre Fenaux, MD PhD, Claude Gardin

Blood (2014) 124 (21): 1921.

https://doi.org/10.1182/blood.V124.21.1921.1921

Published: 2014

Journal Articles

Therapeutic Strategies in Patients with Atypical CML (aCML) and Unclassified MDS/MPN (MDS/MPN-U). a Single Center Report

Thorsten Braun, Aziza Debache, Hervé Roudot, Daniel Lusina, Sylvain Thépot, Virginie Eclache, Antoine Martin, Juliette Soret, Stephanie Harel, Sabine Bréchignac, Charikleia Kelaidi, Lionel Adès, MD PhD, Pierre Fenaux, MD PhD, Claude Gardin

Blood (2014) 124 (21): 5610.

https://doi.org/10.1182/blood.V124.21.5610.5610

Published: 2014

Journal Articles

Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents

Argiris S. Symeonidis, Efstathios Kastritis, Sosana Delimpasi, Charikleia Kelaidi, Anastasia Sioni, Michalis Michael, Amalia Vassou, Anna Christoforidou, Panagiotis Repousis, Eudokia M. Mandala, Evangelos Terpos, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3226.

https://doi.org/10.1182/blood.V122.21.3226.3226

Published: 2013

Journal Articles

Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients

Blood (2013) 122 (21): 3130.

https://doi.org/10.1182/blood.V122.21.3130.3130

Published: 2013

Journal Articles

Extreme Thrombocytosis Under Azacitidine in Patients with Myelodysplastic Syndrome

Charikleia Kelaidi, Dimitrios Kokkinidis, Maria Protopappa, Georgios Papaioannou, Ioannis Batsis, Chrysa Apostolou, Kostas Stamatopoulos, MD, Anastasia Athanasiadou, Achilles Anagnostopoulos, Chrysanthi Vadikoliou

Blood (2012) 120 (21): 4961.

https://doi.org/10.1182/blood.V120.21.4961.4961

Published: 2012

Journal Articles

Acute Myeloid Leukemia with Coexpression of Lymphoid-Associated Antigens: Clinicobiological Associations and Prognostic Implications,

Georgia Voutiadou, Konstantina Kotta, Barbara Tachynopoulou, Apostolia Papalexandri, Chryssanthi Vadikolia, Aliki Tsompanakou, Anastasia Athanasiadou, George Papaioannou, Chrysavgi Lalayanni, Niki Stavroyianni, Antonia Syrigou, Charikleia Kelaidi, Maria Papathanasiou, MD, Ioanna Sakellari, Riad Saloum, Kostas Stamatopoulos, MD, Achilles Anagnostopoulos

Blood (2011) 118 (21): 3596.

https://doi.org/10.1182/blood.V118.21.3596.3596

Published: 2011

Journal Articles

Outcomes of Patients with Myelodysplastic Syndromes/Myeloproliferative Neoplasms with Emphasis On MDS/MPN-Unclassified

Charikleia Kelaidi, Varnavas Constantinou, George Papaioannou, Niki Stavroyianni, Chrysanthi Vadikoliou, Damianos Sotiropoulos, Riant Saloum, Theodora Papadaki, Anastasia Athanasiadou, Achilles Anagnostopoulos

Blood (2011) 118 (21): 5025.

https://doi.org/10.1182/blood.V118.21.5025.5025

Published: 2011

Journal Articles

Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q

Cecile Bally, Raphael Itzykson, MD, Berangere Gruson, MD, Dreyfus Francois, Virginie Siguret, Anne-Laure Taksin, Benoit de Renzis, Laurence Legros, Xavier Thomas, MD, PhD, Krimo Bouabdallah, MD, Pascal Chaibi, MD, Charikleia Kelaidi, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2011) 118 (21): 2786.

https://doi.org/10.1182/blood.V118.21.2786.2786

Published: 2011

Journal Articles

Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, Fabien Lebras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, Francois Dreyfus, Jacques Delaunay, Sorin Visanica, Pascal Turlure, MD, Agnes Guerci, Marie Paule Cabrol, Anne Banos, Michel Blanc, Norbert Vey, Virginie Eclache, Sylvie Chevret, Pierre Fenaux

Blood (2010) 116 (21): 976.

https://doi.org/10.1182/blood.V116.21.976.976

Published: 2010

Journal Articles

Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs)

Blood (2010) 116 (21): 442.

https://doi.org/10.1182/blood.V116.21.442.442

Published: 2010

Journal Articles

Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Sophie Park, MD, PhD, Rosa Sapena, Dominique Vassilieff, Charikleia Kelaidi, Dominique Bordessoule, Aspasia Stamatoullas, Stéphane Cheze, Odile Beyne-Rauzy, Norbert Vey, MD, Christian Rose, Agnès Guerci, Shanti Ame, Gerard Tertian, Borhane Slama, MD, Pierre Fenaux, Francois Dreyfus

Blood (2010) 116 (21): 2916.

https://doi.org/10.1182/blood.V116.21.2916.2916

Published: 2010

Journal Articles

High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study.

Blood (2009) 114 (22): 3812.

https://doi.org/10.1182/blood.V114.22.3812.3812

Published: 2009

Journal Articles

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.

Blood (2009) 114 (22): 2764.

https://doi.org/10.1182/blood.V114.22.2764.2764

Published: 2009

Journal Articles

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Blood (2008) 111 (2): 574–582.

https://doi.org/10.1182/blood-2007-06-096370

Published: 2008

Includes: Supplemental data

Journal Articles

Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.

Aline Renneville, Florence Pasquier, Selim Corm, Nathalie Philippe, Charikleia Kelaidi, Catherine Roche-Lestienne, Virginie Eclache, Gerard Michel, Sylvie Castaigne, Pierre Fenaux, Claude Preudhomme

Blood (2007) 110 (11): 2847.

https://doi.org/10.1182/blood.V110.11.2847.2847

Published: 2007

NARROW

Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue

Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG

Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG

Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy

Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study

Long-Term Outcome of Lower-Risk MDS Patients after Immunosuppressive Therapy (IST) with Anti-Thymocyte Globulin (ATG)+/- Cyclosporin A (CsA)

Therapeutic Strategies in Patients with Atypical CML (aCML) and Unclassified MDS/MPN (MDS/MPN-U). a Single Center Report

Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents

Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients

Extreme Thrombocytosis Under Azacitidine in Patients with Myelodysplastic Syndrome

Acute Myeloid Leukemia with Coexpression of Lymphoid-Associated Antigens: Clinicobiological Associations and Prognostic Implications,

Outcomes of Patients with Myelodysplastic Syndromes/Myeloproliferative Neoplasms with Emphasis On MDS/MPN-Unclassified

Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q

Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs)

Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM)

High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study.

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only